Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2126)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 3, 2025

Reference is made to the circular of JW (Cayman) Therapeutics Co. Ltd (the "**Company**") dated May 15, 2025 (the "**Circular**") incorporating, amongst others, the notice (the "**Notice**") of extraordinary general meeting of the Company (the "**EGM**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

At the EGM held on June 3, 2025, the proposed ordinary resolution as set out in the Notice were taken by poll.

As of the date of the EGM, the total number of issued Shares is 416,198,450 Shares. Pursuant to the Listing Rules and as stated in the Circular, Juno and its associates (who, as far as the Directors were aware, is holding an aggregate of 70,231,140 Shares, representing approximately 16.87% of the total issued share capital of the Company as of the date of the EGM) were required to abstain from voting on the resolution at the EGM. As such, the total number of issued Shares entitling the Independent Shareholders to attend and vote for or against the resolution proposed at the EGM was 345,967,310 Shares. There were (i) no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System) and as such no voting rights of treasury shares have been exercised at the EGM; and (ii) no repurchased Shares which are pending cancellation and should therefore be excluded from the total number of Shares in issue for the purposes of the EGM. Save as disclosed above, there was no restriction on any Shareholder casting votes on any of the proposed resolution at the EGM. There was no Share entitling the Shareholders to attend and vote only against the proposed resolution at the EGM. No party has stated its intention in the Circular that it would vote against any proposed resolution or that it would abstain from voting at the EGM.

The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results in respect of the respective resolution proposed at the EGM were as follows:

ORDINARY RESOLUTION		**Number of votes cast and approximate percentage of total number of votes cast**	
		For	**Against**
1.	To hereby approve, ratify and confirm the License Agreement and its execution thereof and implementation of the transactions contemplated thereunder, and to authorize any Director or any other person authorized by the Directors, to sign, execute, perfect and deliver all such documents, instruments and agreements and do all such deeds, acts, matters and things as they consider necessary, desirable or expedient to carry out or give effect to or otherwise in connection with the License Agreement and the transactions contemplated thereunder.	37,879,303 100.00000%	0 0.00000%

The Board consists of eight Directors, four of whom attended the EGM by electronic means. Ms. Xing Gao, Dr. Sungwon Song, Dr. Cheng Liu and Dr. Debra Yu did not attend the EGM due to other work arrangements.

Please refer to the Notice for the full text of the resolution.

As more than 50% of votes were cast in favour of the above resolution, the ordinary resolution was duly passed at the EGM.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Min Liu
Chairman

Shanghai, PRC, June 3, 2025

As at the date of this announcement, the Board comprises Mr. Min Liu as Chairman and executive Director, Dr. Yiping James Li, Ms. Xing Gao, Dr. Sungwon Song, Dr. Cheng Liu as non-executive Directors, and Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu, and Mr Peng Kuan Chan as independent non-executive Directors.

* *For identification purpose only*